Matinas BioPharma Holdings, Inc. (MTNB) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+415.1%

$6.44

vs $1.25 price

Levered DCF

$7.25

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-94.31

Distress zone

Rating

B-

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.29×	-0.1×	-2.05×	-8.33×	-10.02×	-13×	-21.14×	-4.14×
P/B	0.66×	0.33×	2.44×	2.96×	4.04×	4.2×	9.97×	3.62×
P/S	0×	0×	42.86×	34×	6,432.74×	1,691.22×	3,669.82×	487.44×
EV / EBITDA	-0.06×	0.1×	-2.08×	-5.26×	-8.71×	-11.06×	-17.18×	-3.21×
Gross margin	0.0%	0.0%	14.1%	-423.1%	-44090.9%	-8968.8%	-12409.0%	-5568.0%
Operating margin	0.0%	0.0%	-2168.4%	-771.3%	-74954.5%	-15288.4%	-21067.4%	-12230.9%
Net margin	0.0%	0.0%	-2093.2%	-658.6%	-70554.5%	-14177.0%	-19343.4%	-11760.4%
Current ratio	2.79×	3.01×	5.93×	8.06×	11.73×	17.25×	9.66×	4.61×
Debt / equity	0.28×	0.38×	0.18×	0.11×	0.09×	0.06×	0.13×	0.02×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	255.0%	677.9%	1005.9%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	-3041.9%	-12861.8%	-4169.1%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-214.2%	-319.5%	-119.2%	-57.3%	-44.4%	-35.2%	-52.6%	-87.2%
Return on invested capital	-108.1%	-187.1%	-102.7%	-32.7%	-43.0%	-35.7%	-50.3%	-81.3%
Return on assets	-143.5%	-191.8%	-91.4%	-26.6%	-38.0%	-31.6%	-43.2%	-70.6%
Free cash flow yield	-218.6%	-640.1%	-33.0%	-18.5%	-7.3%	-6.5%	-4.4%	-18.6%
Earnings yield	-322.5%	-977.2%	-48.8%	-19.4%	-11.0%	-8.4%	-5.3%	-24.1%
Enterprise value	$562.8K	-$1.9M	$45.7M	$105.6M	$196M	$259.1M	$311.7M	$46.3M
Net debt / EBITDA	0.27×	0.23×	0.06×	0.14×	0.73×	0.37×	0.99×	0.84×
Cash conversion cycle (days)	-252	-36	-199	-14	-23	-9	-22	-16